A window of opportunity trial evaluating safety and tolerability of the vandetanib-eluting radiopaque beads in patients with primary liver cancer and mCRC

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Feb 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Feb 2022 Results (n=8) of an analysis assessing the role of RO beads as fiducial markers for stereotactic liver radiotherapy published in the British Journal of Radiology
11 Oct 2017 New trial record
09 Oct 2017 According to a BTG media release, first patient has been treated in this trial. This trial is supported by the Cancer Research UK Experimental Cancer Medicines Centre and the UCL Cancer Institute and the National Institute for Health Research University College London Hospitals Biomedical Research Centre. Centres for this trial are University College London Hospitals NHS Foundation Trust and the Royal Free Hospital NHS Foundation Trust.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com